ReachRxResearch
Home
Research
Sign Up
  1. Home
  2. Research Hub
  3. Is Calcitonin at 6–12 Months an Appropri…

Is Calcitonin at 6–12 Months an Appropriate Criterion to Define Cure in Medullary Thyroid Carcinoma?

World Journal of Surgery·August 1
SurgeryPractice changingMedullary Thyroid CarcinomaObservational StudyBiomarker MonitoringAdultCalcitonin

Summary

View source

What was studied

This study evaluates whether undetectable calcitonin (Ct) at 6–12 months post-surgery—the ATA-defined criterion for biochemical cure in medullary thyroid carcinoma (MTC)—accurately reflects long-term disease behavior and recurrence risk.

Key findings

The 6–12 month undetectable Ct threshold may not reliably define cure: some patients with early biochemical persistence subsequently normalize Ct, while others with persistent Ct never develop structural disease.

Study limitations

The abstract alone is available; full methodology, sample size, follow-up duration, and quantitative outcomes are not reported here, limiting detailed appraisal.

Clinical implications

Clinicians should interpret a detectable Ct at 6–12 months with caution—it does not always predict structural recurrence. Longer biochemical follow-up may be needed before reclassifying a patient as having persistent or recurrent MTC.

Related Questions

Explore related topics

What calcitonin level after surgery predicts recurrence in medullary thyroid carcinoma?How long should calcitonin be followed after thyroidectomy for MTC before declaring biochemical cure?Does structural recurrence in medullary thyroid carcinoma always correlate with elevated calcitonin?

Publication Details

Year
2026
Journal
World Journal of Surgery
Source
View article
Keep scrolling
More content below.
Up Next